2025 Annual Report of Independent Director (Yu Yuying)
Dear shareholders and representatives:
I, Yu Yuying, as the independent director of Tongyu New Materials (Guangdong) Co., Ltd. (hereinafter referred to as "the Company"), have strictly adhered to the relevant laws and regulations, including the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Management Measures for Independent Directors of Listed Companies, and the Self-Regulatory Guidelines for Listed Companies on the Shenzhen Stock Exchange, as well as the Company's Articles of Association and internal systems. I have diligently fulfilled my duties and responsibilities as an independent director, promoting the Company's lawful and standardized operations, and effectively safeguarding the interests of the Company and all shareholders, especially minority shareholders. Below is my report on the performance of my duties as an independent director in 2025:
I. Basic Information
(1) Work Experience, Professional Background, and Concurrent Positions
I, Yu Yuying, female, born in May 1979, Chinese nationality, without permanent residency abroad, hold a doctoral degree. I have served as an independent director of Pathfinder Holdings Group Co., Ltd. and currently serve as an independent director for Dirui Medical and Kangmei Pharmaceutical. Since July 2008, I have been an associate professor at the Business School of China University of Political Science and Law; since December 2021, I have been an independent director of the Company.
(2) Independence Statement
During the reporting period, I did not hold any position in the Company other than that of independent director, nor did I hold any position in the Company's major shareholders. There are no relationships that hinder my ability to make independent and objective judgments, and I meet the independence requirements set forth in the relevant laws, regulations, and the Company's Articles of Association. In 2025, I conducted a self-assessment of my independence and submitted a report to the Company's board of directors, confirming that I meet the applicable regulatory requirements for serving as an independent director.
II. Performance in 2025
(1) Attendance at Board and Shareholder Meetings
My attendance at board and shareholder meetings in 2025 is as follows: